当前位置: 首页 >> 检索结果
621. Remote Management of Pacemaker Patients With Biennial In-Clinic Evaluation: Continuous Home Monitoring in the Japanese At-Home Study: A Randomized Clinical Trial.
作者: Eiichi Watanabe.;Fumio Yamazaki.;Toshihiko Goto.;Toru Asai.;Toshihiko Yamamoto.;Keiji Hirooka.;Toshiaki Sato.;Atsunobu Kasai.;Marehiko Ueda.;Takeshi Yamakawa.;Yasunori Ueda.;Katsuhito Yamamoto.;Takeshi Tokunaga.;Yoshinao Sugai.;Kazuhiko Tanaka.;Shigeki Hiramatsu.;Tomoharu Arakawa.;Jürgen Schrader.;Niraj Varma.;Kenji Ando.
来源: Circ Arrhythm Electrophysiol. 2020年13卷5期e007734页
Current expert consensus recommends remote monitoring for cardiac implantable electronic devices, with at least annual in-office follow-up. We studied safety and resource consumption of exclusive remote follow-up (RFU) in pacemaker patients for 2 years.
622. Sonothrombolysis Improves Myocardial Dynamics and Microvascular Obstruction Preventing Left Ventricular Remodeling in Patients With ST Elevation Myocardial Infarction.
作者: Miguel O D Aguiar.;Bruno G Tavares.;Jeane M Tsutsui.;Agostina M Fava.;Bruno C Borges.;Mucio T Oliveira.;Alexandre Soeiro.;Jose C Nicolau.;Henrique B Ribeiro.;Hsu P Chiang.;João C N Sbano.;Andrew Goldsweig.;Carlos E Rochitte.;Bernardo B C Lopes.;José A F Ramirez.;Roberto Kalil Filho.;Thomas R Porter.;Wilson Mathias.
来源: Circ Cardiovasc Imaging. 2020年13卷4期e009536页
It has recently been demonstrated that high-energy diagnostic transthoracic ultrasound and intravenous microbubbles dissolve thrombi (sonothrombolysis) and increase angiographic recanalization rates in patients with ST-segment-elevation myocardial infarction. We aimed to study the effect of sonothrombolysis on the myocardial dynamics and infarct size obtained by real-time myocardial perfusion echocardiography and their value in preventing left ventricular remodeling.
623. Impact of Morphine Treatment With and Without Metoclopramide Coadministration on Ticagrelor-Induced Platelet Inhibition in Acute Myocardial Infarction: The Randomized MonAMI Trial.
作者: Mohammed Saad.;Roza Meyer-Saraei.;Suzanne de Waha-Thiele.;Thomas Stiermaier.;Tobias Graf.;Georg Fuernau.;Harald F Langer.;Thomas Kurz.;Janine Pöss.;Jörg Barkhausen.;Steffen Desch.;Ingo Eitel.;Holger Thiele.
来源: Circulation. 2020年141卷16期1354-1356页 624. Personalized Rate-Response Programming Improves Exercise Tolerance After 6 Months in People With Cardiac Implantable Electronic Devices and Heart Failure: A Phase II Study.
作者: John Gierula.;Judith E Lowry.;Maria F Paton.;Charlotte A Cole.;Rowenna Byrom.;Aaron O Koshy.;Hemant Chumun.;Lorraine C Kearney.;Sam Straw.;T Scott Bowen.;Richard M Cubbon.;Anne-Maree Keenan.;Deborah D Stocken.;Mark T Kearney.;Klaus K Witte.
来源: Circulation. 2020年141卷21期1693-1703页
Heart failure with reduced ejection fraction (HFrEF) is characterized by blunting of the positive relationship between heart rate and left ventricular (LV) contractility known as the force-frequency relationship (FFR). We have previously described that tailoring the rate-response programming of cardiac implantable electronic devices in patients with HFrEF on the basis of individual noninvasive FFR data acutely improves exercise capacity. We aimed to examine whether using FFR data to tailor heart rate response in patients with HFrEF with cardiac implantable electronic devices favorably influences exercise capacity and LV function 6 months later.
625. Effects of Acute Colchicine Administration Prior to Percutaneous Coronary Intervention: COLCHICINE-PCI Randomized Trial.
作者: Binita Shah.;Michael Pillinger.;Hua Zhong.;Bruce Cronstein.;Yuhe Xia.;Jeffrey D Lorin.;Nathaniel R Smilowitz.;Frederick Feit.;Nicole Ratnapala.;Norma M Keller.;Stuart D Katz.
来源: Circ Cardiovasc Interv. 2020年13卷4期e008717页
Vascular injury and inflammation during percutaneous coronary intervention (PCI) are associated with increased risk of post-PCI adverse outcomes. Colchicine decreases neutrophil recruitment to sites of vascular injury. The anti-inflammatory effects of acute colchicine administration before PCI on subsequent myocardial injury are unknown.
626. Impact of Cardiac Implantable Electronic Device Infection: A Clinical and Economic Analysis of the WRAP-IT Trial.
作者: Bruce L Wilkoff.;Giuseppe Boriani.;Suneet Mittal.;Jeanne E Poole.;Charles Kennergren.;G Ralph Corey.;John C Love.;Ralph Augostini.;Svein Faerestrand.;Sherman S Wiggins.;Jeff S Healey.;Reece Holbrook.;Jeffrey D Lande.;Daniel R Lexcen.;Sarah Willey.;Khaldoun G Tarakji.; .
来源: Circ Arrhythm Electrophysiol. 2020年13卷5期e008280页
Current understanding of the impact of cardiac implantable electronic device (CIED) infection is based on retrospective analyses from medical records or administrative claims data. The WRAP-IT (Worldwide Randomized Antibiotic Envelope Infection Prevention Trial) offers an opportunity to evaluate the clinical and economic impacts of CIED infection from the hospital, payer, and patient perspectives in the US healthcare system.
627. Echocardiographic Results of Transcatheter Versus Surgical Aortic Valve Replacement in Low-Risk Patients: The PARTNER 3 Trial.
作者: Philippe Pibarot.;Erwan Salaun.;Abdellaziz Dahou.;Eleonora Avenatti.;Ezequiel Guzzetti.;Mohamed-Salah Annabi.;Oumhani Toubal.;Mathieu Bernier.;Jonathan Beaudoin.;Géraldine Ong.;Julien Ternacle.;Laura Krapf.;Vinod H Thourani.;Raj Makkar.;Susheel K Kodali.;Mark Russo.;Samir R Kapadia.;S Chris Malaisrie.;David J Cohen.;Jonathon Leipsic.;Philipp Blanke.;Mathew R Williams.;James M McCabe.;David L Brown.;Vasilis Babaliaros.;Scott Goldman.;Wilson Y Szeto.;Philippe Généreux.;Ashish Pershad.;Maria C Alu.;Ke Xu.;Erin Rogers.;John G Webb.;Craig R Smith.;Michael J Mack.;Martin B Leon.;Rebecca T Hahn.; .
来源: Circulation. 2020年141卷19期1527-1537页
This study aimed to compare echocardiographic findings in low-risk patients with severe aortic stenosis after surgical aortic valve replacement (SAVR) or transcatheter aortic valve replacement (TAVR).
628. Clinical and Economic Implications of Inconclusive Noninvasive Test Results in Stable Patients With Suspected Coronary Artery Disease: Insights From the PROMISE Trial.
作者: Akash Goyal.;Neha Pagidipati.;C Larry Hill.;Brooke Alhanti.;James E Udelson.;Michael H Picard.;Patricia A Pellikka.;Udo Hoffmann.;Daniel B Mark.;Pamela S Douglas.
来源: Circ Cardiovasc Imaging. 2020年13卷4期e009986页
Inconclusive noninvasive tests complicate the care of patients with suspected coronary artery disease, but their prevalence and impact on management, outcomes, and costs are not well described.
629. Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention: A Subgroup Analysis From the REDUAL PCI Trial.
作者: Natalia C Berry.;Laura Mauri.;Philippe Gabriel Steg.;Deepak L Bhatt.;Stefan H Hohnloser.;Matias Nordaby.;Corinna Miede.;Takeshi Kimura.;Gregory Y H Lip.;Jonas Oldgren.;Jurriën M Ten Berg.;Christopher P Cannon.
来源: Circ Cardiovasc Interv. 2020年13卷4期e008349页
The REDUAL PCI trial (Evaluation of Dual Therapy With Dabigatran vs Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting) demonstrated that, in patients with atrial fibrillation following percutaneous coronary intervention, bleeding risk was lower with dabigatran plus clopidogrel or ticagrelor (dual therapy) than warfarin plus clopidogrel or ticagrelor and aspirin (triple therapy). Dual therapy was noninferior for risk of thromboembolic events. Whether these results apply equally to patients at higher risk of ischemic events due to lesion complexity or clinical risk factors is unclear.
630. Hypertrophic Cardiomyopathy With Left Ventricular Systolic Dysfunction: Insights From the SHaRe Registry.
作者: Peter Marstrand.;Larry Han.;Sharlene M Day.;Iacopo Olivotto.;Euan A Ashley.;Michelle Michels.;Alexandre C Pereira.;Samuel G Wittekind.;Adam Helms.;Sara Saberi.;Daniel Jacoby.;James S Ware.;Steven D Colan.;Christopher Semsarian.;Jodie Ingles.;Neal K Lakdawala.;Carolyn Y Ho.; .
来源: Circulation. 2020年141卷17期1371-1383页
The term "end stage" has been used to describe hypertrophic cardiomyopathy (HCM) with left ventricular systolic dysfunction (LVSD), defined as occurring when left ventricular ejection fraction is <50%. The prognosis of HCM-LVSD has reportedly been poor, but because of its relative rarity, the natural history remains incompletely characterized.
631. Ten-Year Outcomes After Drug-Eluting Stents Versus Coronary Artery Bypass Grafting for Left Main Coronary Disease: Extended Follow-Up of the PRECOMBAT Trial.
作者: Duk-Woo Park.;Jung-Min Ahn.;Hanbit Park.;Sung-Cheol Yun.;Do-Yoon Kang.;Pil Hyung Lee.;Young-Hak Kim.;Do-Sun Lim.;Seung-Woon Rha.;Gyung-Min Park.;Hyeon-Cheol Gwon.;Hyo-Soo Kim.;In-Ho Chae.;Yangsoo Jang.;Myung-Ho Jeong.;Seung-Jea Tahk.;Ki Bae Seung.;Seung-Jung Park.; .
来源: Circulation. 2020年141卷18期1437-1446页
Long-term comparative outcomes after percutaneous coronary intervention (PCI) with drug-eluting stents and coronary-artery bypass grafting (CABG) for left main coronary artery disease are highly debated.
632. Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial.
作者: Gregory G Schwartz.;Philippe Gabriel Steg.;Michael Szarek.;Vera A Bittner.;Rafael Diaz.;Shaun G Goodman.;Yong-Un Kim.;J Wouter Jukema.;Robert Pordy.;Matthew T Roe.;Harvey D White.;Deepak L Bhatt.; .
来源: Circulation. 2020年141卷20期1608-1617页
Patients with acute coronary syndrome are at risk for peripheral artery disease (PAD) events and venous thromboembolism (VTE). PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors reduce lipoprotein(a) and low-density lipoprotein cholesterol (LDL-C) levels. Our objective was to ascertain whether PCSK9 inhibition reduces the risk of PAD events or VTE after acute coronary syndrome, and if such effects are related to levels of lipoprotein(a) or LDL-C.
633. Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial.
作者: Deepak L Bhatt.;John W Eikelboom.;Stuart J Connolly.;P Gabriel Steg.;Sonia S Anand.;Subodh Verma.;Kelley R H Branch.;Jeffrey Probstfield.;Jackie Bosch.;Olga Shestakovska.;Michael Szarek.;Aldo Pietro Maggioni.;Petr Widimský.;Alvaro Avezum.;Rafael Diaz.;Basil S Lewis.;Scott D Berkowitz.;Keith A A Fox.;Lars Ryden.;Salim Yusuf.; .
来源: Circulation. 2020年141卷23期1841-1854页
Patients with established coronary artery disease or peripheral artery disease often have diabetes mellitus. These patients are at high risk of future vascular events.
634. Bivalirudin Versus Heparin Monotherapy in Elderly Patients With Myocardial Infarction: A Prespecified Subgroup Analysis of the VALIDATE-SWEDEHEART Trial.
作者: Axel Wester.;Rubina Attar.;Moman A Mohammad.;Nazim Isma.;Stefan James.;Elmir Omerovic.;David Erlinge.;Sasha Koul.
来源: Circ Cardiovasc Interv. 2020年13卷4期e008671页
Elderly patients with acute myocardial infarction undergoing percutaneous coronary intervention are at increased risk of both ischemic and bleeding complications. The optimal anticoagulation strategy in these patients is uncertain. Therefore, we compared bivalirudin to heparin monotherapy in a contemporary cohort of such patients.
635. Low-Attenuation Noncalcified Plaque on Coronary Computed Tomography Angiography Predicts Myocardial Infarction: Results From the Multicenter SCOT-HEART Trial (Scottish Computed Tomography of the HEART).
作者: Michelle C Williams.;Jacek Kwiecinski.;Mhairi Doris.;Priscilla McElhinney.;Michelle S D'Souza.;Sebastien Cadet.;Philip D Adamson.;Alastair J Moss.;Shirjel Alam.;Amanda Hunter.;Anoop S V Shah.;Nicholas L Mills.;Tania Pawade.;Chengjia Wang.;Jonathan Weir McCall.;Michael Bonnici-Mallia.;Christopher Murrills.;Giles Roditi.;Edwin J R van Beek.;Leslee J Shaw.;Edward D Nicol.;Daniel S Berman.;Piotr J Slomka.;David E Newby.;Marc R Dweck.;Damini Dey.
来源: Circulation. 2020年141卷18期1452-1462页
The future risk of myocardial infarction is commonly assessed using cardiovascular risk scores, coronary artery calcium score, or coronary artery stenosis severity. We assessed whether noncalcified low-attenuation plaque burden on coronary CT angiography (CCTA) might be a better predictor of the future risk of myocardial infarction.
636. Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease.
作者: John W Stanifer.;Sean D Pokorney.;Glenn M Chertow.;Stefan H Hohnloser.;Daniel M Wojdyla.;Samira Garonzik.;Wonkyung Byon.;Ziad Hijazi.;Renato D Lopes.;John H Alexander.;Lars Wallentin.;Christopher B Granger.
来源: Circulation. 2020年141卷17期1384-1392页
Compared with the general population, patients with advanced chronic kidney disease have a >10-fold higher burden of atrial fibrillation. Limited data are available guiding the use of nonvitamin K antagonist oral anticoagulants in this population.
637. Randomized Comparison of Everolimus- and Zotarolimus-Eluting Coronary Stents With Biolimus-Eluting Stents in All-Comer Patients.
作者: Young Jin Youn.;Jun-Won Lee.;Sung Gyun Ahn.;Seung-Hwan Lee.;Junghan Yoon.;Keum Soo Park.;Jin Bae Lee.;Sang-Yong Yoo.;Do-Sun Lim.;Jang Hyun Cho.;Cheol Ung Choi.;Myung Ho Jeong.;Kyoo-Rok Han.;Kwang Soo Cha.;Sung Yun Lee.;Hyun-Hee Choi.;Jae Woong Choi.;Min Su Hyon.;Moo-Hyun Kim.
来源: Circ Cardiovasc Interv. 2020年13卷3期e008525页
There is limited data comparing the Xience everolimus-eluting stent (EES) and the Resolute zotarolimus-eluting stent (ZES) with the BioMatrix biolimus-eluting stent (BES).
638. Sex-Specific Management in Patients With Acute Myocardial Infarction and Cardiogenic Shock: A Substudy of the CULPRIT-SHOCK Trial.
作者: Maria Rubini Gimenez.;Uwe Zeymer.;Steffen Desch.;Suzanne de Waha-Thiele.;Taoufik Ouarrak.;Janine Poess.;Roza Meyer-Saraei.;Steffen Schneider.;Georg Fuernau.;Janina Stepinska.;Kurt Huber.;Stephan Windecker.;Gilles Montalescot.;Stefano Savonitto.;Raban V Jeger.;Holger Thiele.
来源: Circ Cardiovasc Interv. 2020年13卷3期e008537页
Women are more likely to suffer and die from cardiogenic shock (CS) as the most severe complication of acute myocardial infarction. Data concerning optimal management for women with CS are scarce. Aim of this study was to better define characteristics of women experiencing CS and to the influence of sex on different treatment strategies.
639. White Blood Cells and Blood Pressure: A Mendelian Randomization Study.
作者: Mateusz Siedlinski.;Ewelina Jozefczuk.;Xiaoguang Xu.;Alexander Teumer.;Evangelos Evangelou.;Renate B Schnabel.;Paul Welsh.;Pasquale Maffia.;Jeanette Erdmann.;Maciej Tomaszewski.;Mark J Caulfield.;Naveed Sattar.;Michael V Holmes.;Tomasz J Guzik.
来源: Circulation. 2020年141卷16期1307-1317页
High blood pressure (BP) is a risk factor for cardiovascular morbidity and mortality. While BP is regulated by the function of kidney, vasculature, and sympathetic nervous system, recent experimental data suggest that immune cells may play a role in hypertension.
640. Association of Intensive Lifestyle Intervention, Fitness, and Body Mass Index With Risk of Heart Failure in Overweight or Obese Adults With Type 2 Diabetes Mellitus: An Analysis From the Look AHEAD Trial.
作者: Ambarish Pandey.;Kershaw V Patel.;Judy L Bahnson.;Sarah A Gaussoin.;Corby K Martin.;Ashok Balasubramanyam.;Karen C Johnson.;Darren K McGuire.;Alain G Bertoni.;Dalane Kitzman.;Jarett D Berry.; .
来源: Circulation. 2020年141卷16期1295-1306页
Type 2 diabetes mellitus (T2DM) is associated with a higher risk for heart failure (HF). The impact of a lifestyle intervention and changes in cardiorespiratory fitness (CRF) and body mass index on risk for HF is not well established.
|